the quodria team

John is an experienced scientist and entrepreneur with over 20 years of experience in both large and small Pharma. John has led drug discovery programs from concept into late-stage clinical development. He founded Blueberry Therapeutics and Tecrea Ltd and has completed multi-million dollar commercial deals.

David has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College London. He has worked in the pharmaceutical industry for more than 20 years and is an experienced leader in drug discovery and development. He has taken products from concept through to late-stage clinical testing.

Mark is a chartered management accountant and experienced finance leader with significant finance and business experience in bioscience, major pharmaceutical and other global R&D-led companies.

Scott is a seasoned global innovation leader with over 20 years of experience in consumer health and personal care, having spearheaded R&D and regulatory strategies for iconic brands such as Scholl, Dettol, Rexona, Dove, and Durex. Renowned for his ability to drive innovation and market access he has delivered approximately 40 global, multi-million dollar innovations. 

Julie holds a PhD from Imperial College London and has over 7 years of academic post-doctoral experience both in the UK at the Institute for Cancer Research and the University of Nottingham and in the USA at Harvard Medical School. Since transitioning from academia, Julie has spent more than 15 years in the pharmaceutical industry in both big Pharma and biotech. At Blueberry Therapeutics, Julie established the laboratory infrastructure and developed a portfolio of new topical treatments for common dermatological diseases. Throughout her career she has remained committed to laboratory research and brings to Quodria her deep and extensive knowledge in the development of novel topical formulations, as well as the creation and validation of biochemical and immunoassays, cell biology and ex vivo tissue assays.

Sinead graduated from the University of Nottingham with a degree in Medicinal and Biological Chemistry, but her true expertise lies in physical chemistry. Sinead honed her analytical skills at LGC and Alderley Analytical working on small-molecule drug discovery solutions before moving to Blueberry Therapeutics where she led the development of analytical methods. Sinead now joins Quodria to provide key analytical support for drug product development. She has specialised in chromatography systems, focusing on developing assays for complex nanomedicines. Sinead provides key analytical support for our projects, leveraging her extensive knowledge of LC-MS and GxP practices to develop and validate the critical assays required for successful formulation development.